Despite many years of research, no biomarkers for stroke are available to use in clinical
practice. Progress in high-throughput technologies has provided new opportunities to …

Ischemic stroke (IS) is a multifactorial and heterogeneous neurological disorder with high
rate of death and long-term impairment. Despite years of studies, there are still no stroke …

Stroke remains one of the leading causes of long-term disability and mortality despite recent
advances in acute thrombolytic therapies. In fact, the global lifetime risk of stroke in adults …

Stroke remains a leading cause of death and disability, with limited therapeutic options and
suboptimal tools for diagnosis and prognosis. High throughput technologies such as …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Stroke is the largest single cause of
disability in the UK. While tests based upon biomarkers have been around for decades …

Introduction Ischemic stroke (IS) is a major contributor to the global disease burden, and
effective biomarkers for IS management in clinical practice are urgently needed …

Biomarkers provide critical mechanistic insights to key biologic processes that occur during
cerebral ischemia which, when carefully applied, can improve clinical decision-making in …

Finding ischemic stroke biomarker is highly desirable because it can improve diagnosis
even before a patient arrives to the hospital. Metabolome is one of new technologies that …

Ischemic stroke is a sudden loss of brain function due to the reduction of blood flow. Brain
tissues cease to function with subsequent activation of the ischemic cascade. Metabolomics …

Background: Distinguishing between stroke subtypes and knowing the time of stroke onset
are critical in clinical practice. Thrombolysis and thrombectomy are very effective treatments …